199 related articles for article (PubMed ID: 25354137)
1. Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.
Burden-Teh E; Wootton CI; Williams HC
Br J Dermatol; 2015 Apr; 172(4):861-6. PubMed ID: 25354137
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
3. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
4. [Management of cutaneous leishmaniasis in adults and children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2005 Nov; 65(5):487-95. PubMed ID: 16465821
[TBL] [Abstract][Full Text] [Related]
5. Oral miltefosine to treat new world cutaneous leishmaniasis.
Soto J; Toledo JT
Lancet Infect Dis; 2007 Jan; 7(1):7. PubMed ID: 17182338
[No Abstract] [Full Text] [Related]
6. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran.
Iraji F; Sadeghinia A
Ann Trop Med Parasitol; 2005 Jan; 99(1):3-9. PubMed ID: 15701249
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
[No Abstract] [Full Text] [Related]
8. Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Carneiro G; Aguiar MG; Fernandes AP; Ferreira LA
Expert Opin Drug Deliv; 2012 Sep; 9(9):1083-97. PubMed ID: 22724539
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cutaneous leishmaniasis with 20% paromomycin ointment.
Stanimirović A; Stipić T; Skerlev M; Basta-Juzbasić A
J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):214-7. PubMed ID: 10642059
[TBL] [Abstract][Full Text] [Related]
10. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
Stojkovic M; Junghanss T; Krause E; Davidson RN
Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
[TBL] [Abstract][Full Text] [Related]
11. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
13. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
14. Treatment of New World cutaneous leishmaniasis with miltefosine.
Soto J; Berman J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
[TBL] [Abstract][Full Text] [Related]
15. Topical paromomycin for New World cutaneous leishmaniasis.
Sosa N; Pascale JM; Jiménez AI; Norwood JA; Kreishman-Detrick M; Weina PJ; Lawrence K; McCarthy WF; Adams RC; Scott C; Ransom J; Tang D; Grogl M
PLoS Negl Trop Dis; 2019 May; 13(5):e0007253. PubMed ID: 31048871
[TBL] [Abstract][Full Text] [Related]
16. Leishmania tropica in children: a retrospective study.
Solomon M; Schwartz E; Pavlotsky F; Sakka N; Barzilai A; Greenberger S
J Am Acad Dermatol; 2014 Aug; 71(2):271-7. PubMed ID: 24775403
[TBL] [Abstract][Full Text] [Related]
17. Interventions for American cutaneous and mucocutaneous leishmaniasis.
González U; Pinart M; Rengifo-Pardo M; Macaya A; Alvar J; Tweed JA
Cochrane Database Syst Rev; 2009 Apr; (2):CD004834. PubMed ID: 19370612
[TBL] [Abstract][Full Text] [Related]
18. Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica.
Killingley B; Lamb LE; Davidson RN
Ann Trop Med Parasitol; 2009 Mar; 103(2):171-5. PubMed ID: 19208301
[No Abstract] [Full Text] [Related]
19. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
20. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
Ruiz-Villaverde R; Sánchez-Cano D; Villaverde-Gutierrez C
J Eur Acad Dermatol Venereol; 2007 May; 21(5):695-6. PubMed ID: 17447994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
